Bogdanov / Licha Molecular Imaging

An Essential Tool in Preclinical Research, Diagnostic Imaging, and Therapy
1. Auflage 2007
ISBN: 978-3-540-26809-3
Verlag: Springer Berlin Heidelberg
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band 49, 258 Seiten

Reihe: Ernst Schering Foundation Symposium Proceedings

The continuous progress in the understanding of molecular processes of disease formation and progression attributes an increasing importance to biomedical molecular imaging methods. The purpose of this workshop was to discuss and overview multiple applications and emerging technologies in the area of diagnostic imaging including its fundamental capabilities in preclinical research, the opportunities for medical care, and the options involving therapeutic concepts. The book provides the reader with state-of-the-art information on the different aspects of diagnostic imaging, illuminating new developments in molecular biology, imaging agents and molecular probe design, and therapeutic techniques.

Autoren/Hrsg.

Bogdanov, Alexei

Licha, Kai

Inhaltsverzeichnis

1;Preface;5
2;Contents;7
3;List of Editors and Contributors;9
4;1 Oligonucleotides as Radiopharmaceuticals;13
4.1;1.1 Imaging of Oligonucleotides;17
4.2;1.2 Imaging In Vivo Pharmacokinetics and Biodistribution of Oligonucleotides;20
4.3;1.3 Comparative Pharmaco-Imaging of Oligonucleotides;21
4.4;1.4 Evaluation of Delivery Vectors for Oligonucleotides;23
4.5;1.5 Imaging with Oligonucleotides;25
4.6;1.6 Antisense Oligonucleotides for Gene-Related Disease Therapy;26
4.7;1.7 Improving Antisense for In Vivo Applications;27
4.8;1.8 In Vivo Imaging Studies with Antisense Oligonucleotides;28
4.9;1.9 Aptamer Oligonucleotides;30
4.10;1.10 Applications and Therapeutic Aptamers;33
4.11;1.11 Aptamers as Contrast Agents for Diagnosis;34
4.12;1.12 Future Developments Needed for In Vivo Imaging with Oligonucleotides: Mastering the Nonspecific Interactions and Signal-to-Noise Ratio;35
4.13;References;38
5;2 ImagingProtein-Protein Interactions in Whole Cells and Living Animals;47
5.1;2.1 Two-Hybrid Systems;48
5.2;2.2 Protein-Fragment Complementation;49
5.3;2.3 Optimized Luciferase Fragment Complementation;50
5.4;2.4 Conclusions;51
5.5;References;52
6;3 Radiolabeled Peptides in Nuclear Oncology: Influence of Peptide Structure and Labeling Strategy on Pharmacology;54
6.1;3.1 Introduction;54
6.2;3.2 Design of Peptide-Based Radiopharmaceuticals;58
6.3;3.3 Preclinical Characterization of Somatostatin-Based Radiopeptides;69
6.4;3.4 Patient Studies;77
6.5;3.5 Summary and Conclusions;80
6.6;References;80
7;4 Pretarieted Radioimmunotherapy;84
8;5 PET/CT:Combining Function and Morphology;96
8.1;5.1 General Considerations in PET and PET/CT;96
8.2;5.2 PET/CT in Oncology;98
8.3;5.3 PET/CT and Radiation Treatment Planning;104
8.4;5.4 PET/CT in Cardiology;104
8.5;5.5 Conclusions;106
8.6;References;107
9;6 High Relaxivity Contrast Agents for MRI and Molecular Imaging;110
9.1;6.1 Introduction;110
9.2;6.2 Determinants of Relaxivity;114
9.3;6.3 How to Improve Relaxivity?;116
9.4;6.4 Targeting Cells with Gd(III) Chelates;122
9.5;6.5 Concluding Remarks;129
9.6;References;130
10;7 Luminescent Lanthanide Complexes as Sensors and Imaiini Proies;133
10.1;7.1 Introduction and Background;133
10.2;7.2 Mechanistic Approach to Modulation of Luminescence;137
10.3;7.3 Tailoring the Lanthanide Complex for Use "In Cellulo";144
10.4;7.4 Conclusions and Future Perspectives;152
10.5;References;153
11;8 Mainetic Resonance Signal Amplification Probes;157
11.1;8.1 Receptor-Mediated Internalization;158
11.2;8.2 Enzyme-Mediated MR Signal Amplification;162
11.3;References;166
12;9 Imaging of Proteases for Tumor Detection and Differentiation;168
12.1;9.1 Introduction;168
12.2;9.2 Light for Molecular Imaging;169
12.3;9.3 Optical Contrast Agents;170
12.4;9.4 Nononcological Imaging;174
12.5;9.5 Potential Clinical Applications;175
12.6;References;177
13;10 Molecular Imaging with Targeted Ultrasound Contrast Microiuiiles;180
13.1;10.1 Introduction;180
13.2;10.2 Microbubble-Based Ultrasound Contrast Agents: General Design and Preparation;182
13.3;10.3 Targeting Ligand Attachment to Microbubbles;185
13.4;10.4 In Vitro Targeting: Binding Studies in Model Systems;189
13.5;10.5 In Vivo Microbubble Targeting: Biodistribution, Nonspecific and Targeted Accumulation and Ultrasound Imaging;192
13.6;10.6 Conclusions;197
13.7;References;198
14;11 Noninvasive Real-Time In Vivo Bioluminescent Imaging of Gene Expression and of Tumor Progression and Metastasis;201
14.1;11.1 General Introduction;202
14.2;11.2 Principles of Bioluminescent Imaging;202
14.3;11.3 Transgenic Luc-Reporter Mice to Study Specific Gene Expression;204
14.4;11.4 Tumor Progression and Bone/Bone Marrow Metastasis of Breast and Prostate Cancer;213
14.5;11.5 Use of Bioluminescent Imaging in Animal Models of Skeletal Metastasis;220
14.6;11.6 Conclusions and Future Perspectives;228
14.7;References;228
15;12 Tarieted Optical Imaging and Photodynamic Therapy;236
15.1;12.1 Introduction;236
15.2;12.2 Photosensitizer Localization in Tumors;238
15.3;12.3 Photosensitizing Agents;240
15.4;12.4 Targeted Optical Imaging and Photodynamic Therapy;246
15.5;12.5 Optical Targeting;252
15.6;12.6 Photodynamic Therapy;256
15.7;12.7 Conclusion;258
16;References;259